These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

258 related items for PubMed ID: 9387205

  • 1. Interferon-alpha therapy in polycythemia vera and essential thrombocythemia.
    Elliott MA, Tefferi A.
    Semin Thromb Hemost; 1997; 23(5):463-72. PubMed ID: 9387205
    [Abstract] [Full Text] [Related]

  • 2. Leukemogenic risk of hydroxyurea therapy in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.
    Nand S, Stock W, Godwin J, Fisher SG.
    Am J Hematol; 1996 May; 52(1):42-6. PubMed ID: 8638610
    [Abstract] [Full Text] [Related]

  • 3. Polycythemia vera and essential thrombocythemia: 2013 update on diagnosis, risk-stratification, and management.
    Tefferi A.
    Am J Hematol; 2013 Jun; 88(6):507-16. PubMed ID: 23695894
    [Abstract] [Full Text] [Related]

  • 4. Polycythemia vera and essential thrombocythemia: 2012 update on diagnosis, risk stratification, and management.
    Tefferi A.
    Am J Hematol; 2012 Mar; 87(3):285-93. PubMed ID: 22331582
    [Abstract] [Full Text] [Related]

  • 5. Expertise-based management in essential thrombocythemia and polycythemia vera.
    Finazzi G, Barbui T.
    Cancer J; 2007 Mar; 13(6):372-6. PubMed ID: 18032974
    [Abstract] [Full Text] [Related]

  • 6. Annual Clinical Updates in Hematological Malignancies: a continuing medical education series: polycythemia vera and essential thrombocythemia: 2011 update on diagnosis, risk-stratification, and management.
    Tefferi A.
    Am J Hematol; 2011 Mar; 86(3):292-301. PubMed ID: 21351120
    [Abstract] [Full Text] [Related]

  • 7. [Successful treatment with interferon-alpha in a case of acute myeloid leukemia with del (20q) following polycythemia vera].
    Sumi M, Tauchi T, Takaku T, Ohyashiki JH, Ohyashiki K.
    Rinsho Ketsueki; 2005 Nov; 46(11):1208-12. PubMed ID: 16440805
    [Abstract] [Full Text] [Related]

  • 8. Polycythemia vera and essential thrombocythemia: 2019 update on diagnosis, risk-stratification and management.
    Tefferi A, Barbui T.
    Am J Hematol; 2019 Jan; 94(1):133-143. PubMed ID: 30281843
    [Abstract] [Full Text] [Related]

  • 9. [Use of interferon in the treatment of chronic myeloproliferative disorders].
    Robak T.
    Acta Haematol Pol; 1992 Jan; 23(2 Suppl 1):30-7. PubMed ID: 1488870
    [Abstract] [Full Text] [Related]

  • 10. Therapy for polycythemia vera and essential thrombocythemia is driven by the cardiovascular risk.
    Barbui T, Finazzi G.
    Semin Thromb Hemost; 2007 Jun; 33(4):321-9. PubMed ID: 17525889
    [Abstract] [Full Text] [Related]

  • 11. Risk-adapted therapy in essential thrombocythemia and polycythemia vera.
    Finazzi G, Barbui T.
    Blood Rev; 2005 Sep; 19(5):243-52. PubMed ID: 15963833
    [Abstract] [Full Text] [Related]

  • 12. Myelofibrosis with myeloid metaplasia: the advanced phase of an untreated disseminated hematological cancer. Time to change our therapeutic attitude with early upfront treatment?
    Hasselbalch HC.
    Leuk Res; 2009 Jan; 33(1):11-8. PubMed ID: 18632152
    [Abstract] [Full Text] [Related]

  • 13. Polycythemia vera and essential thrombocythemia in young patients.
    Frezzato M, Ruggeri M, Castaman G, Rodeghiero F.
    Haematologica; 1993 Jan; 78(6 Suppl 2):11-7. PubMed ID: 8039752
    [Abstract] [Full Text] [Related]

  • 14. [Interferon-alpha in the treatment of myeloproliferative syndromes].
    Ballarino P, Castello G, Lerza R.
    Recenti Prog Med; 1994 Nov; 85(11):546-50. PubMed ID: 7855389
    [Abstract] [Full Text] [Related]

  • 15. Pathogenetic mechanisms in chronic myeloproliferative disorders: polycythemia vera, essential thrombocythemia, agnogenic myeloid metaplasia, and chronic myelogenous leukemia.
    Tefferi A.
    Semin Hematol; 1999 Jan; 36(1 Suppl 2):3-8. PubMed ID: 9930550
    [Abstract] [Full Text] [Related]

  • 16. Proposal for revised diagnostic criteria of essential thrombocythemia and polycythemia vera by the Thrombocythemia Vera Study Group.
    Michiels JJ, Juvonen E.
    Semin Thromb Hemost; 1997 Jan; 23(4):339-47. PubMed ID: 9263350
    [Abstract] [Full Text] [Related]

  • 17. Long-term effects of the treatment of polycythemia vera with recombinant interferon-alpha.
    Silver RT.
    Cancer; 2006 Aug 01; 107(3):451-8. PubMed ID: 16804923
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.